Quick Answer
Tarsus Pharmaceuticals, Inc. reported R&D Expense of $64.32 million for fiscal year 2025.
Tarsus Pharmaceuticals, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $64.32M | +20.5% |
| 2024 | $53.39M | +6.1% |
| 2023 | $50.31M | +18.0% |
| 2022 | $42.62M | +2.2% |
| 2021 | $41.71M | +121.6% |
| 2020 | $18.83M | +495.4% |
| 2019 | $3.16M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $16.28M | +34.3% | +4.4% |
| June 30, 2025 | $15.59M | +26.6% | +8.2% |
| March 31, 2025 | $14.41M | +19.4% | +18.8% |
| September 30, 2024 | $12.13M | +0.2% | -1.6% |
| June 30, 2024 | $12.32M | -1.8% | +2.1% |
| March 31, 2024 | $12.07M | -2.3% | -0.3% |
| September 30, 2023 | $12.11M | +10.9% | -3.5% |
| June 30, 2023 | $12.55M | +30.6% | +1.5% |
- Tarsus Pharmaceuticals, Inc. showed an increase of +20.5% in R&D Expense compared to the prior fiscal year.
- Over the 2019–2025 period, Tarsus Pharmaceuticals, Inc.’s r&d expense has grown by 1934.2% (from $3.16 million to $64.32 million).
- The most recent figure is from Tarsus Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: